Cargando…

Prevention of cardiovascular disease: are we successful?( )

Detalles Bibliográficos
Autor principal:	De Backer, Guy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Invited Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583179/ https://www.ncbi.nlm.nih.gov/pubmed/36284644 http://dx.doi.org/10.1093/ehjopen/oeac062

Ejemplares similares

Cardiovascular disease and male sexual dysfunction
por: Miner, Martin, et al.
Publicado: (2015)

Do We Have the Spark?
por: Rupel, Valentina Prevolnik, et al.
Publicado: (2022)

Poor Clinician Adherence to Inflammatory Bowel Disease Guidelines: How Do We Remedy the Situation?
por: Hart, Lara, et al.
Publicado: (2022)

A Call to Action to Address the Burden of Cardiovascular Disease in People with Diabetes
por: Lorenty, Karolay, et al.
Publicado: (2022)

Cardiovascular disease prevention in women: are we up to date?
por: Rapeport, Naomi
Publicado: (2011)

2022: the year in cardiovascular disease – the year of upfront lipid lowering combination therapy
por: Banach, Maciej, et al.
Publicado: (2022)

Vaginal mesh: What lessons have we learnt?
por: Robinson, Dudley, et al.
Publicado: (2020)

Side effects related to systemic cancer treatment: are we changing the Promethean experience with molecularly targeted therapies?
por: De Angelis, Carlo
Publicado: (2008)

Trends in Cardiovascular Disease Mortality: Can We Prevent PRECISELY?
por: Sung, Ki-Chul
Publicado: (2021)

Successful Implementation of Integrated Care in Slovenian Primary Care
por: Susič, Antonija Poplas, et al.
Publicado: (2020)

Peer Support in the Management of Diabetes to Improve Cardiovascular Disease Outcomes in Low- and Middle-Income Countries (LMICs)
por: Ferrari, Gina, et al.
Publicado: (2023)

Do we always need anticoagulation before cardioversion of atrial fibrillation in ladies?
por: Görenek, Bülent, et al.
Publicado: (2016)

Doctors and COVID-19: Why we need to be a wise human first!
por: Gore, Gouri Adwaita
Publicado: (2020)

Predicting the outcome of normal pressure hydrocephalus therapy—where do we stand?
por: Oertel, Joachim M. K., et al.
Publicado: (2021)

Conclusions about testosterone therapy and cardiovascular risk
por: Anawalt, Bradley D, et al.
Publicado: (2018)

Managing the toxicities of the FEC-100 followed by docetaxel regimen: The price of success
por: Laing, Kara
Publicado: (2008)

Aspirin for primary prevention of cardiovascular disease: Advice for a decisional strategy based on risk stratification
por: Aimo, Alberto, et al.
Publicado: (2020)

The Impact of Alcohol Consumption on Cardiovascular Health: Myths and Measures
por: Arora, Monika, et al.
Publicado: (2022)

What do the “new” Pulmonary Hypertension Guidelines tell us: should we change our practice?
por: Kaymaz, Cihangir, et al.
Publicado: (2016)

Why is understanding the relationship of testosterone to cardiovascular risk so important?
por: Yeap, Bu B, et al.
Publicado: (2018)

Climate Action for Health: An Urgent Call from the Global Cardiovascular Community
por: Pinto, Fausto J., et al.
Publicado: (2021)

Preventing aggressive prostate cancer with proven cardiovascular disease preventive methods
por: Moyad, Mark A
Publicado: (2015)

Providing Pneumococcal Vaccines Reduces the Risk of Serious Infections From Pneumococcal Pneumonia. We Should Consider a Simplified Immunization Schedule
por: Almasry, Mazen, et al.
Publicado: (2023)

Preventing treatment delays for benign gynaecological conditions
por: Robinson, Dudley
Publicado: (2022)

Clean Air, Smart Cities, Healthy Hearts: Action on Air Pollution for Cardiovascular Health
por: Brauer, Michael, et al.
Publicado: (2021)

Editorial: gut microbial profile associated with primary sclerosing cholangitis—what is new and how do we progress from here? Authors’ reply
por: Rühlemann, Malte, et al.
Publicado: (2019)

The preventive treatment of recurrent stone-formation: how can we improve compliance in the treatment of patients with recurrent stone disease?
por: Kok, Dirk Jan
Publicado: (2015)

Evinacumab – The new kid on the block. Is it important for cardiovascular prevention?
por: Surma, Stanisław, et al.
Publicado: (2021)

Primary stroke prevention in China – a new approach
por: Feigin, Valery L., et al.
Publicado: (2015)

E-Cigarettes: A New Threat to Cardiovascular Health – A World Heart Federation Policy Brief
por: Bianco, Eduardo, et al.
Publicado: (2021)

Taking a Stand Against Air Pollution – The Impact on Cardiovascular Disease: A Joint Opinion from the World Heart Federation, American College of Cardiology, American Heart Association, and the European Society of Cardiology
por: Brauer, Michael, et al.
Publicado: (2021)

Taking a Stand Against Air Pollution—The Impact on Cardiovascular Disease: A Joint Opinion from the World Heart Federation, American College of Cardiology, American Heart Association, and the European Society of Cardiology
por: Brauer, Michael, et al.
Publicado: (2021)

Critical Question in Cardiovascular Risk: Can we use clinical trials to improve the outcomes of patients with hypertension?
por: Kostis, John B.
Publicado: (2021)

Developing an operational research model for strengthening policy and programs on prevention and control of hypertension in India
por: Goel, Sonu
Publicado: (2022)

Editorial: mesalazine to prevent recurrent acute diverticulitis—the final nail in the coffin. Authors’ reply
por: Kruis, W., et al.
Publicado: (2017)

Preventing the Next Pandemic: The Case for Investing in Circulatory Health – A Global Coalition for Circulatory Health Position Paper
por: Ferat, Leslie Rae, et al.
Publicado: (2021)

Sex steroids and cardiovascular disease
por: Yeap, Bu Beng
Publicado: (2014)

TAM receptors in cardiovascular disease
por: McShane, Lucy, et al.
Publicado: (2019)

MicroRNA and Cardiovascular Diseases
por: Çakmak, Hüseyin Altuğ, et al.
Publicado: (2020)

Mesenchymal stromal cells for cardiovascular disease
por: Copland, Ian B.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_8bjodq54c1duk54kp1v49s02lv